MUC5B启动子变异不预测系统性硬化症相关间质性肺病进展
本研究纳入参与硬皮病肺研究(SLS)II的142例系统性硬化症相关间质性肺病(SSc-ILD)患者,检测MUC5B启动子变异rs35705950,并分析其与用力肺活量(FVC)变化及影像学纤维化变化的关系。128例受检者中18%携带至少一个MUC5B次要等位基因拷贝,该变异未影响FVC病程,也未影响任一治疗组(环磷酰胺或吗替麦考酚酯)的影像学纤维化、磨玻璃影或ILD评分变化。
要点
- MUC5B rs35705950在SSc-ILD受检者中检出率为18%,在非裔美国人中罕见(3.7%)。
- 携带该变异与否在年龄、性别、SSc亚型及ILD疾病严重度上相似。
- 该变异未预测FVC病程变化,也未影响对环磷酰胺或吗替麦考酚酯的治疗反应。
核心结论
- 在SSc-ILD随机对照试验背景下,MUC5B变异的存在不预测疾病严重度,也不影响对MMF或CYC的治疗反应。
研究设计与样本
- 纳入参与硬皮病肺研究(SLS)II(MMF对比CYC)的SSc-ILD患者(N=142),采用TaqMan基因分型法检测MUC5B rs35705950单核苷酸多态性。
- 使用联合模型检验该变异对2年内FVC病程的影响,并用线性回归模型分析其与定量影像学纤维化变化的关系。
主要发现
- 128例受检者中18%携带至少一个MUC5B次要等位基因拷贝。
- 携带至少一个该等位基因拷贝的患者与不携带者在年龄、性别、SSc亚型及ILD疾病严重度方面相似。
- 该变异在非裔美国人中罕见(3.7%)。
- 该变异的存在未影响FVC病程,也未影响任一治疗组中定量影像学纤维化、磨玻璃影或ILD评分的变化。
关键数值与推荐
- MUC5B rs35705950检出率:128例受检者中18%携带至少一个次要等位基因拷贝。
- 非裔美国人中该变异罕见:3.7%。
临床怎么用
- 对于SSc-ILD患者,检测MUC5B rs35705950不宜用于预测疾病严重度或指导MMF与CYC的选择。
局限性
- 研究基于SLS II随机对照试验人群,作者指出尚需在其他SSc队列及接受抗纤维化治疗的患者中进一步研究该变异是否影响ILD进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the prevalence of the MUC5B promoter variant rs35705950 in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) and whether its presence predicts response to immunosuppression with cyclophosphamide (CYC) and mycophenolate (MMF). METHODS: SSc-ILD patients who participated in Scleroderma Lung Study (SLS) II (MMF versus CYC) were included in this study (N = 142). TaqMan Genotyping Assays were used to determine the MUC5B rs35705950 single nucleotide polymorphism. Joint models were created to examine how the presence of this variant affected the course of the forced vital capacity (FVC) over 2 years. Linear regression models were used to investigate the relationship between the presence of this variant and the change in quantitative radiographic fibrosis. RESULTS: Among 128 participants who were tested for this variant, 18% possessed at least one copy of the MUC5B minor allele. Patients with at least one copy of this allele were similar to those without the allele with respect to age, sex, SSc subtype, ILD disease severity; however, this variant was rare among African Americans (3.7%). The presence of the MUC5B variant did not affect the course of the FVC, nor the change in quantitative radiographic fibrosis, ground glass or ILD scores in either treatment arm. CONCLUSION: In the context of a randomized controlled trial for SSc-ILD, the presence of the MUC5B variant did not predict disease severity, nor affect treatment response to MMF or CYC. Future studies are needed to determine whether this variant affects ILD progression in other SSc cohorts and in patients receiving anti-fibrotic therapy.
引用
- Volkmann ER, Tashkin DP, Roth MD, et al. The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. Semin Arthritis Rheum. 2020. PMID: 32906032. doi:10.1016/j.semarthrit.2020.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。